These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Hassan C; Zullo A; Ierardi E; Burattini O; De Francesco V; Morini S Gut; 2006 Apr; 55(4):589-90. PubMed ID: 16531548 [No Abstract] [Full Text] [Related]
3. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435 [TBL] [Abstract][Full Text] [Related]
4. Infliximab in ulcerative colitis. Aberra FN; Lichtenstein GR Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815 [TBL] [Abstract][Full Text] [Related]
5. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. Fratila OC; Craciun C J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047 [TBL] [Abstract][Full Text] [Related]
7. The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data. Rossetti S; Actis GC; Fadda M; Rizzetto M; Palmo A Dig Liver Dis; 2004 Jun; 36(6):426-31. PubMed ID: 15248385 [TBL] [Abstract][Full Text] [Related]